SCYNEXIS

SCYNEXIS EBITDA CAGR 5Y

EBITDA CAGR (5 Year) of SCYNEXIS (SCYX) as of Oct 22, 2026.

EBITDA CAGR 5Y

-

Last updated:

EBITDA CAGR (5 Year) of SCYNEXIS is 2026 - . EBITDA CAGR (5 Year) of SCYNEXIS was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

On Eulerpool you can find the complete historical development of EBITDA CAGR (5 Year) SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

The 5-year EBITDA CAGR shows the compound annual growth rate of EBITDA over five years.

To evaluate EBITDA CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA CAGR (5 Year).

EBITDA CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA CAGR (5 Year)'s SCYNEXIS historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — SCYNEXIS

All Key Metrics — SCYNEXIS